Clinical Trial

Evaluation of the Predictive Impact of Serum S100B and S100B Polymorphisms on Postoperative Cognitive Dysfunction and Delirium

Completed
View on ClinicalTrials.gov →
Summary
Postoperative cognitive disorders, including postoperative cognitive dysfunction (POCD) and postoperative delirium (POD), are common complications following surgery and anesthesia, particularly in vulnerable patient populations. These conditions are associated with increased morbidity, prolonged hospitalization, and higher healthcare costs. Early identification of patients at risk remains challenging, and reliable biomarkers are needed to improve perioperative risk stratification. S100B protein has been proposed as a biomarker of neuronal injury and blood-brain barrier dysfunction. In addition, genetic variations in the S100B gene may influence individual susceptibility to postoperative cognitive impairment. The aim of this prospective cohort study is to evaluate the association between perioperative serum S100B levels, S100B gene polymorphisms, and postoperative cognitive disorders. Furthermore, the predictive value of perioperative changes in S100B levels for postoperative cognitive dysfunction and delirium will be investigated.
Trial Details
NCT Number NCT07509372
Lead Sponsor Ankara University
Conditions Postoperative Cognitive Dysfunction, Delirium, Postoperative
Enrollment 137 participants
Start Date 2023-09-27
Primary Completion 2024-11-06 (estimated)
Study Completion 2024-11-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-03